Clinical trial research led by Dana-Farber's Toni Choueiri, MD, finds immunotherapy drug given after surgery delays recurrence in patients with kidney cancer. Study presented at #ASCO21 during plenary session. Press Release: http://ms.spr.ly/6051VAaBx Video published: June 3, 2021 promise for kidney cancer patients Considered high risk for relapse, a new study shows encouraging results of an immunotherapy drug given after surgery. So this is the first evidence of something really positive and we believe is clinically meaningful. Dana Farber Cancer Institute's Dr Tony Sherry is leading the study that looks at an immunotherapy drug called Pemberley is a math given following partial or radical Knaperek to me, which is the removal of the cancerous kidney, This patient, we know that our A relatively high risk of recurrence and in this, um, you know, trial Pemba realism A led to a 32% decrease in the risk of recurrence or death, Dr Sherry says. Past studies that have looked at using immunotherapy after surgery in these high risk patients have not shown a consistent benefit, He says. Researchers are continuing to follow the nearly 1000 patients enrolled in this phase three clinical trial to see how they do over a longer period of time. The very important key secondary endpoint is overall survival. Does this therapy lead to a decrease in the risk of death overall, and actually the early signs are quite promising, Doctor Sherry says there were side effects consistent with what they've seen in other cancer types. Where Pemberley is a mob is in use, he says. More research is needed to build on these successes in kidney cancer, to explore combination therapies after surgery and also to look for biomarkers specific to individual patients. I think bio market remain important because there are patients in our study that very likely are cured only with surgery and didn't need any therapy. And there are patients who received embolism ob and still with that did progress. So how do we handle both city scans and imaging alone are not enough. So hopefully with liquid biopsies and, uh, you know other biomarkers will be able to do way more precision medicine here.